Small cell lung cancer: Where do we go from here?

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

2011 • 9,173 citations

Comprehensive molecular profiling of lung adenocarcinoma

2014 • 5,023 citations

Comprehensive genomic characterization of squamous cell lung cancers

2012 • 3,654 citations

Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

2013 • 3,211 citations

Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission

1999 • 1,607 citations

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

1999 • 1,394 citations

Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer

2014 • 1,394 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

2012 • 1,296 citations

Targeting MYC dependence in cancer by inhibiting BET bromodomains

2011 • 1,054 citations

Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer

2007 • 1,015 citations

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

2012 • 996 citations

The BATTLE Trial: Personalizing Therapy for Lung Cancer

2011 • 860 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

2014 • 650 citations

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

2003 • 594 citations

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

2012 • 589 citations

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

2009 • 507 citations

Results of the Two Incidence Screenings in the National Lung Screening Trial

2013 • 499 citations

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

2012 • 479 citations

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by CultureIn vitro

2009 • 428 citations

The Aurora kinase family in cell division and cancer

2008 • 406 citations

High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.

2000 • 400 citations

Molecular genetics of small cell lung carcinoma

2001 • 378 citations

Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer

2004 • 376 citations

Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress

1999 • 351 citations

A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

2013 • 338 citations

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

2006 • 321 citations

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma

2013 • 278 citations

Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles

2004 • 241 citations

Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma

2010 • 236 citations

Histopathologic classification of small cell lung cancer changing concepts and terminology

1988 • 220 citations

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

2010 • 215 citations

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors

1993 • 207 citations

The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern

1992 • 199 citations

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

2009 • 195 citations

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

2009 • 193 citations

Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis

2006 • 177 citations

p53 mutations in human lung tumors.

1992 • 177 citations

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer

2005 • 175 citations

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

2012 • 171 citations

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

2012 • 169 citations

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

2013 • 168 citations

Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

2008 • 164 citations

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

2005 • 154 citations

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer

2002 • 148 citations

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

2005 • 148 citations

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

2010 • 141 citations

Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma

1997 • 129 citations

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

2014 • 126 citations

A Meta-Analysis of the Timing of Chest Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer

2004 • 98 citations

Aurora A Is Essential for Early Embryonic Development and Tumor Suppression

2008 • 97 citations

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

2012 • 94 citations

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

2009 • 93 citations

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

2014 • 85 citations

Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

2004 • 83 citations

Progress in the therapy of small cell lung cancer

2003 • 83 citations

Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

2013 • 71 citations

Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer

2004 • 67 citations

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

2013 • 57 citations

Progress in the management of limited‐stage small cell lung cancer

2013 • 56 citations

Array‐based comparative genomic hybridization analysis of high‐grade neuroendocrine tumors of the lung

2005 • 56 citations

Expression of the tyrosine kinase c‐kit is an independent prognostic factor in patients with small cell lung cancer

2004 • 52 citations

Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

2014 • 37 citations

Basic treatment considerations using chemotherapy for patients with small cell lung cancer

2004 • 35 citations

Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry

2013 • 25 citations

Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE).

2013 • 24 citations

Perspective: Opportunities in recalcitrant, rare and neglected tumors

2013 • 10 citations